Majid Momeny Selected Research

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Leukemia, Pre B Cell)

2/2022	Synergistic effects of BKM120 and panobinostat on pre-B acute lymphoblastic cells: an emerging perspective for the simultaneous inhibition of PI3K and HDACs.
5/2020	Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF-κB and autophagy on panobinostat cytotoxicity.
10/2018	Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-κB axis: Shedding new light on resistance to Aprepitant.
1/2017	PI3K-δ inhibition using CAL-101 exerts apoptotic effects and increases doxorubicin-induced cell death in pre-B-acute lymphoblastic leukemia cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Majid Momeny Research Topics

Disease

40	Neoplasms (Cancer) 01/2022 - 10/2007
8	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 03/2010
7	Acute Promyelocytic Leukemia 03/2019 - 09/2010
6	Breast Neoplasms (Breast Cancer) 01/2021 - 06/2010
6	Adenocarcinoma 09/2020 - 06/2010
4	Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Leukemia, Pre B Cell) 02/2022 - 01/2017
3	Glioma (Gliomas) 12/2021 - 03/2010
3	Carcinogenesis 09/2020 - 01/2018
3	Inflammation (Inflammations) 01/2020 - 01/2017
3	Neoplasm Metastasis (Metastasis) 06/2019 - 10/2007
3	Carcinoma (Carcinomatosis) 01/2017 - 03/2016
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 05/2021 - 01/2021
2	Mitochondrial Diseases (Mitochondrial Disease) 01/2021 - 08/2020
2	Prostatic Neoplasms (Prostate Cancer) 09/2020 - 12/2011
2	Neuroinflammatory Diseases 08/2020 - 01/2017
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 05/2020 - 01/2017
2	Leukemia 10/2018 - 10/2017
2	Colitis 12/2017 - 07/2016
2	Cardiotoxicity 09/2016 - 09/2010
2	Hepatocellular Carcinoma (Hepatoma) 01/2013 - 09/2008
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2021
1	Schizophrenia (Dementia Praecox) 01/2021
1	Ovarian Neoplasms (Ovarian Cancer) 01/2020
1	Hematologic Neoplasms (Hematological Malignancy) 03/2019
1	Multiple Myeloma 01/2019
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/2018
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2018
1	Migraine Disorders (Migraine) 01/2018

Drug/Important Bio-Agent (IBA)

11	Arsenic Trioxide (Trisenox)FDA Link 01/2022 - 09/2010
9	Pharmaceutical PreparationsIBA 01/2021 - 06/2010
5	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 12/2021 - 01/2017
5	Silybin (Lagosa)IBA 03/2016 - 09/2008
4	NVP-BKM120IBA 02/2022 - 10/2017
4	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2022 - 01/2018
4	Phosphotransferases (Kinase)IBA 01/2021 - 01/2018
4	Proteins (Proteins, Gene)FDA Link 01/2021 - 09/2008
3	PanobinostatIBA 02/2022 - 05/2020
3	idelalisibIBA 02/2022 - 01/2017
3	cediranib (AZD2171)IBA 12/2021 - 02/2020
3	Telomerase (Telomerase Reverse Transcriptase)IBA 03/2019 - 10/2007
3	Morphine (MS Contin)FDA LinkGeneric 01/2018 - 09/2016
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2018 - 12/2016
2	3- (4- methylphenylsulfonyl)- 2- propenenitrileIBA 01/2022 - 01/2018
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2021 - 09/2020
2	Histone Deacetylases (Histone Deacetylase)IBA 05/2021 - 05/2020
2	Tyrosine Kinase InhibitorsIBA 05/2021 - 01/2021
2	Neurotransmitter Agents (Neurotransmitter)IBA 01/2021 - 12/2016
2	Streptozocin (Streptozotocin)FDA Link 08/2020 - 01/2017
2	EnzymesIBA 05/2020 - 12/2016
2	Toll-Like Receptor 4IBA 01/2020 - 06/2019
2	Biological ProductsIBA 01/2020 - 01/2013
2	ethyl 6- (N- (2- chloro- 4- fluorophenyl)sulfamoyl)cyclohex- 1- ene- 1- carboxylateIBA 01/2020 - 06/2019
2	Trastuzumab (Herceptin)FDA Link 11/2019 - 08/2019
2	dacomitinibIBA 08/2019 - 01/2017
2	ErbB Receptors (EGF Receptor)IBA 08/2019 - 01/2017
2	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2019 - 12/2018
2	Vincristine (Oncovin)FDA LinkGeneric 01/2019 - 01/2018
2	Thalidomide (Thalomid)FDA Link 01/2018 - 01/2017
2	LithiumIBA 11/2017 - 09/2010
2	SurvivinIBA 04/2017 - 09/2010
2	tivozanibIBA 01/2017 - 01/2017
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2017 - 09/2010
2	Neuregulin-1 (Neuregulin 1)IBA 03/2016 - 02/2015
2	Cathepsin BIBA 01/2016 - 03/2010
2	Matrix Metalloproteinases (MMPs)IBA 02/2015 - 10/2007
2	GelatinIBA 09/2012 - 10/2007
2	NF-kappa B (NF-kB)IBA 09/2010 - 03/2010
2	Messenger RNA (mRNA)IBA 09/2010 - 09/2008
1	Gentian Violet (Violet, Crystal)FDA Link 01/2022
1	Dual-Specificity PhosphatasesIBA 01/2022
1	Annexin A5IBA 01/2022
1	Immune Checkpoint InhibitorsIBA 10/2021
1	Clozapine (Clozaril)FDA LinkGeneric 01/2021
1	Imatinib Mesylate (Gleevec)FDA Link 01/2021
1	Disulfiram (Antabuse)FDA Link 01/2021
1	Drug CombinationsIBA 01/2021
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021
1	Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA 01/2021
1	Minocycline (Cyclops)FDA LinkGeneric 08/2020
1	Histone Deacetylase InhibitorsIBA 05/2020
1	Interleukin-6 (Interleukin 6)IBA 01/2020
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	Transcription Factors (Transcription Factor)IBA 01/2020
1	neratinibIBA 11/2019
1	Cetuximab (Erbitux)FDA Link 08/2019
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 08/2019
1	MicroRNAs (MicroRNA)IBA 03/2019
1	BIBR 1532IBA 03/2019
1	carfilzomibIBA 01/2019
1	Aprepitant (Emend)FDA Link 10/2018
1	Neurokinin-1 Receptors (Neurokinin 1 Receptor)IBA 10/2018
1	Poly (ADP-Ribose) Polymerase-1IBA 06/2018
1	DNA (Deoxyribonucleic Acid)IBA 06/2018
1	Long Noncoding RNAIBA 05/2018
1	AZD 6244IBA 01/2018

Therapy/Procedure

21	Therapeutics 01/2022 - 01/2011
4	Drug Therapy (Chemotherapy) 01/2022 - 04/2017
1	Molecular Targeted Therapy 01/2022
1	Immunotherapy 10/2021
1	Castration 09/2020